Merck & Co IncChange company Symbol lookupSelect an option...MRK Merck & Co IncFCELB Fuelcell Energy IncUK Ucommune International LtdCRDF Cardiff Oncology IncTRNR Interactive Strength IncOMGA Omega Therapeutics IncACST Acasti Pharma IncPYPD PolyPid LtdACRX AcelRx Pharmaceuticals IncMI Nft LtdGo
Change company Symbol lookup
Select an option...
MRK Merck & Co Inc
FCELB Fuelcell Energy Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
MI Nft Ltd
Health Care : Pharmaceuticals | Large Cap Blend
Company profileMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. It sells human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Company’s Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products as well as health management solutions for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s product MK-7240 is used for the treatment of immune-mediated diseases including ulcerative colitis, and Crohn’s disease.
|
|
|
|
| |
| Latest Earnings Beat Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 1, 2023 | -$2.06 | Q2 Consensus of 19 analysts | -$2.18 | Difference from consensus | 5.37% | Q3 Earnings will announce | (Unconfirmed) October 26, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
MRK's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.